On December 2, 2024, BioVie announced the registration of up to 7,711,613 shares of Class A common stock for resale by selling stockholders. These shares are issuable upon the exercise of various warrants, including Private Placement I and II Warrants, and Placement Agent Warrants I-V. The company will not receive proceeds from the resale but will gain nominal cash from warrant exercises.The shares are registered to satisfy rights granted under agreements with ThinkEquity LLC, acting as placement agent. The stockholders may sell shares in different ways, with selling expenses borne by them. BioVie intends to use any proceeds from warrant exercises for working capital and corporate purposes.BioVie's common stock is traded on Nasdaq under the symbol "BIVI," with a closing price of $3.51 on November 19, 2024. Investors are advised to review risk factors before purchasing these securities.

On December 2, 2024, BioVie announced the registration of up to 7,711,613 shares of Class A common stock for resale by selling stockholders. These shares are issuable upon the exercise of various warrants, including Private Placement I and II Warrants, and Placement Agent Warrants I-V. The company will not receive proceeds from the resale but will gain nominal cash from warrant exercises.The shares are registered to satisfy rights granted under agreements with ThinkEquity LLC, acting as placement agent. The stockholders may sell shares in different ways, with selling expenses borne by them. BioVie intends to use any proceeds from warrant exercises for working capital and corporate purposes.BioVie's common stock is traded on Nasdaq under the symbol "BIVI," with a closing price of $3.51 on November 19, 2024. Investors are advised to review risk factors before purchasing these securities.